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The structures of caspases-1, -3, -7 and -8 reveal the basis for
substrate and inhibitor selectivity
Yunyi Wei, Ted Fox, Steve P Chambers, JoAnne Sintchak, Joyce T Coll, Julian
MC Golec, Lora Swenson, Keith P Wilson and Paul S Charifson
Background: Peptide inhibitors of caspases have helped define the role of
these cysteine proteases in biology. Structural and biochemical characterization
of the caspase enzymes may contribute to the development of new drugs for
the treatment of caspase-mediated inflammation and apoptosis. 
Results: The crystal structure of the previously unpublished caspase-7 (Csp7;
2.35 Å) bound to the reversible tetrapeptide aldehyde inhibitor acetyl-
Asp–Glu–Val–Asp-CHO is compared with crystal structures of caspases-1
(2.3 Å), -3 (2.2 Å), and -8 (2.65 Å) bound to the same inhibitor. Csp7 is a close
homolog of caspase-3 (Csp3), and these two caspases possess some
quarternary structural characteristics that support their unique role among the
caspase family. However, although Csp3 and Csp7 are quite similar overall,
they were found to have a significantly different substitution pattern of amino
acids in and around the S4-binding site. 
Conclusions: These structures span all three caspase subgroups, and provide
a basis for inferring substrate and inhibitor binding, as well as selectivity for the
entire caspase family. This information will influence the design of selective
caspase inhibitors to further elucidate the role of caspases in biology and hopefully
lead to the design of therapeutic agents to treat caspase-mediated diseases,
such as rheumatoid arthritis, certain neurogenerative diseases and stroke.
Introduction
The caspase (Csp) enzymes are receiving increasing atten-
tion as targets for the design of new drugs, and reviews of
this family of cysteine proteases are abundant [1–6]. The
Csp family can be divided into three subfamilies, based on
their predominant functional roles and their substrate
specificities [5,7]. The family members most closely
related to Csp1 (also known as interleukin-1β converting
enzyme [ICE]) are mainly involved in pro-inflammatory
events. Inhibitors of these enzymes have potential as anti-
inflammatory drugs for use in diseases such as rheumatoid
arthritis [8]. The remaining caspases are of central impor-
tance in the pathways controlling apoptosis. Inhibitors of
these enzymes may lead to compounds useful for the treat-
ment of an array of diseases, such as stroke and neurode-
generation, for which there are few effective therapies.
Peptidic caspase inhibitors have already shown efficacy in
models of myocardial infarction [9], stroke [10,11], trau-
matic brain injury, [12] and fulminant liver disease [13]. 
The first orally active inhibitor of Csp1, VX740, has been
reported recently [14]. The design of VX740 started with
the crystal structure of the complex of Csp1 with the
tetrapeptide aldehyde acetyl-Tyr–Val–Ala–Asp-CHO
(Ac-YVAD-CHO). In this work, we report the crystallo-
graphic complexes of Csp1, Csp3, Csp8, and the first
reported structure of Csp7, all bound to the same
tetrapeptide aldehyde inhibitor, acetyl-Asp–
Glu–Val–Asp-CHO (Ac-DEVD-CHO). Examination of
this new data, coupled with that from previously pub-
lished complexes of Csp1 [15–18], Csp3 [19,20] and Csp8
[21,22] gives invaluable information for the design of
inhibitors of all three Csp families. 
Results and discussion
Crystallography
The model quality of all four structures was assessed using
PROCHECK [23] and the crystallographic statistics are
given in Table 1. 
The Csp7–Ac-DEVD-CHO complex is similar to the
Csp3–Ac-DEVD-CHO complex
The refined model of Csp7 contains a complete catalytic
unit comprising two p20–p10 heterodimers. The p20 and
p10 polypeptide chains are composed of residues 57–196
and 212–302, respectively. The two interdigitating 
heterodimers associate to form a tetramer of globular
shape. A ribbon stereo diagram of the Csp7 complex is
illustrated in Figure 1. As expected, the overall fold of
Csp7 is very similar to that of Csp1, Csp3 and Csp8. All
four subunits contribute to a total of 12 strands comprising
the central β sheet. This forms the core of the enzyme,
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which is flanked by ten α helixes approximately parallel to
the β strands. In particular, the β-sheet structure of the
p20 domain, which contains the catalytic His285 and
Cys186 residues, has a crossing-over –1X, +2X, +1X
linking topology according to Richardson’s definition [24].
This motif has been widely observed in serine hydrolases,
most notably the α/β hydrolase superfamily [25]. 
Among the three subfamilies of caspases, Csp7 belongs to
the second group that includes Csp2 and Csp3. Aside from
the differences that exist in the propeptide and linker
regions, Csp7 is structurally and functionally very similar
to Csp3. In fact, Csp7 and Csp3 can be superimposed
without any amino acid deletions or insertions along the
polypeptide chains (Figure 2a) with a root mean square
(RMS) deviation of 0.37 Å for backbone Cα atoms.
Sequence alignment and Cα atom superpositioning of
Csp1, Csp3, Csp7 and Csp8 spanning all three caspase
subfamilies (Figures 2a and 3) demonstrated that the main
differences between their folds are in three regions. These
differences occur in the two loops on the prime side and a
third loop proximal to the S4 binding site (Figure 2a). 
Similar to Csp3, Csp7 also has a single-residue deletion
within the strand C290–M294 (Figure 3), which pairs with
its symmetry-related equivalent forming the tetrameric
424 Chemistry & Biology 2000, Vol 7 No 6
Table 1
Crystallographic data and refinement statistics.
Csp1 Csp3 Csp7 Csp8
X-ray experiments
Temperature (K) 266 270 100 100
X-ray radiation Rotating anode Rotating anode χ= 5 at BNL‡ BNL
Wavelength (Å) 1.5418 1.5418 1.10 1.09
Space group P43212 P212121 P3221 C2221
a(Å) 62.45 89.46 88.18 62.12
b(Å) 62.45 97.33 88.18 344.33
c(Å) 162.36 70.09 186.23 190.99
α(º) 90 90.0 90 90
β(º) 90 90.0 90 90
γ(º) 90 90.0 120 90
No of p20/p10 in asym. unit 1 2 2 6
Recording apparatus Raxis IIC Raxis IIC CCD 2X2K CCD 2X2K
Resolution (Å) 2.5 2.2 2.35 2.65
Total observation 48936 63425 139781 189632
Unique reflection 13468 12532 34359 53183
Completeness (%) 93 92 96.6 88.2
Rsym* (%) 6.5 7.8 8.3 5.5
Structure solution
Methods See [16] MR MR MR
Search model See [16] PolyAla of Csp1 PolyAla of Csp3 PolyAla of Csp3
Resolution range (Å ) See [16] 8.0–2.8 16.0–4.0 16.0–4.0
Software See [16] AmoRe AmoRe AmoRe
R-factor (%) See [16] 45.1 41.0 34.7
Correlation coefficient Factor See [16] 54.6 61.0 72.5
Refinement
Resolution range (Å) 7.5–2.5 8.0–2.2 7.5–2.35 20.0–2.65
Sigma cut off (σ) 2.5 3.0 2.5 2.5
Programs X-PLOR X-PLOR X-PLOR X-PLOR
No of reflections 14,658 24,890 33,303 48,348
R-factor† (%) 23.1 18.9 18.5 21.9
Free R-factor† (%) 28.2 24.7 26.3 28.6
Stereochemical parameters
Rms bond distance (Å) 0.011 0.009 0.009 0.006
Rms bond angle (°) 2.3 1.9 1.8 1.7
Rms dihedral angle (°) 24.1 23.6 23.4 23.4
Nonglycine residues in the regions of most favored (%) 90.0 89.3 89.0 86.3
Additional allowed (%) 9.5 9.0 10.5 13.7
Generously allowed (%) 0.5 0.7 0.5 0.0
Disallowed (%) 0 0 0 0.0
*Rsym = Σ|Ii–<I>|/ΣIi, where Ii and <I> are the intensities for the ith observation and mean of the reflection, respectively.
†R-factor = Σ|Fobs–Fcal|/Σ|Fobs|, where Fobs and Fcal are observed and calculated model structure factors. Free R-factor was calculated with 5% of
each data set not used in the refinement. ‡ Brookhaven National Laboratories.
assembly of the enzyme. In Csp1 and other caspases of
group 1, there is an arginine residue (R391 in Csp1) which
causes a bulge in the β strand and consequently induces a
rotation of one heterodimer relative to the other. In Csp3
[20] and Csp7, the two dimeric subunits are significantly
less twisted. The combination of this single deletion and
greater hydrophobic nature of this strand in Csp3 and
Csp7 has not only changed the quaternary structures of
these enzymes but also reshaped the central cavity formed
at the interface of the two heterodimers. The central
cavity of the Csp7 tetramer was occupied by 24 water mol-
ecules. As this central cavity is adjacent to the prime side
of the substrate binding site, it may not effect directly
substrate binding to Csp3 and Csp7. However, the varia-
tion in the central cavity among caspases might be an
important determinant of macromolecular substrate recog-
nition in the apoptosis cascade.
Binding of Ac-DEVD–CHO to caspases from all three
subfamilies
The four caspases included in this study span three differ-
ent functional and phylogenetic groups of caspases, and
each exhibits subtle differences in the way they bind
Ac-DEVD-CHO. The peptide inhibitor has adopted an
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Figure 1
Stereoview of Csp7 tetrameric assembly
made using RIBBONS [46]. The p20, p10
and their symmetry related equivalents, p20′
and p10′, are shown in green, yellow, blue
and violet, respectively. The ball-and-stick
model shown in cyan represents the Ac-
DEVD-CHO inhibitor.
Figure 2
Secondary structural elements of Csp1, Csp3,
Csp7 and Csp8. (a) Conserved fold for
superimposed Csp1 (cyan), Csp3 (violet),
Csp7 (yellow), Csp8 (green) with covalently
bound tetrapeptide inhibitor, Ac-DEVD-CHO.
(b) Superimposed S4 loops for Csp1
(378–386), Csp3 (244–262), Csp7
(270–288) and Csp8 (451–463). (c) Prime
side helix–turn–helix insertion in Csp8 ranging
from residues 245–253 proximal to
superimposed insertion loop of Csp1
(Figure 2c: residues 249–254). Panels (b) and
(c) have been rotated slightly relative to (a). 
extended conformation in all four complexes. Besides the
fact that the catalytic dyad and two residues anchoring the
aspartate residue in the P1 position are from the p20
domain, most of the intimate contacts are between the
tetrapeptide and the groups from the p10 subunit.
Although there are differences in some of the amino acid
residues from each caspase that contribute to binding Ac-
DEVD-CHO, the overall conformation of the inhibitor is
highly conserved. A schematic comparing Ac-DEVD-
CHO binding to Csp1, Csp3, Csp7 and Csp8 is shown in
Figure 4, whereas Figure 5 shows the surface features of
the respective binding sites. We will now consider the
similarities and differences with which each of the four
caspases binds each of the tetrapeptide P1–P4 residues. 
At the P1 site, all four of the complexes show that the
inhibitor is covalently bound to the nucleophilic cysteine
residue in the active site (Figure 4), although binding to
the classic oxyanion hole was not observed. In each case,
the thiohemiacetal oxygen resulting from nucleophilic
thiol attack on the aldehyde carbonyl forms a hydrogen
bond with the adjacent histidine that comprises the
enzyme’s cysteine–histidine dyad. In addition, the thio-
hemiacetal oxygen in all four complexes makes hydrogen
bonds of varying strength to the nucleophilic cysteine
backbone nitrogen and conserved glycine backbone nitro-
gen. Previous work [15,20] has shown that some irre-
versible inhibitors exhibit classic oxyanion hole-binding to
Csp1 and Csp3. The other interactions at P1 are also strik-
ingly conserved among the four structures. In every case,
there are charge–charge interactions between the P1
aspartate sidechain and two arginine residues, as well as a
hydrogen bond with a conserved glutamine. Figure 5
shows the conserved nature of this overwhelmingly elec-
tropositive site and the buried nature of the P1 aspartate.
Additionally, each complex retains a hydrogen bond
between the P1 backbone nitrogen and the backbone car-
bonyl of a conserved serine.
For the P2 valine of Ac-DEVD-CHO, the overall nature of
the hydrophobic interaction is conserved, but there are
subtle differences in the χ1 value for the valine sidechain,
depending on the residues comprising the S2 pocket.
Interestingly, Csp3 and Csp7 possess an extra residue
(phenylalanine) which contributes to the S2 site and is also
part of the S4 loop. Csp8 also possesses an aromatic residue
(Tyr365) at roughly the same spatial position as Phe256 of
Csp3 and Phe282 of Csp7, but this tyrosine residue is part
of an extended strand near the carboxyl terminus of the
p20 subunit. Residues corresponding to Tyr365 of Csp8
are Pro290 (Csp1), Leu168 (Csp3), and Leu191 (Csp7).
None of these contribute directly to the S2 site in the cor-
responding complexes with Ac-DEVD-CHO. 
The P3 glutamic acid of the tetrapeptide inhibitor, makes
at least one charge–charge interaction with a conserved
arginine in all four caspase complexes (Figure 4). Addi-
tionally, the P3 backbone nitrogen and carbonyl oxygen of
the P3 glutamic acid make strong hydrogen bonds with
the respective backbone carbonyl oxygen and nitrogen of
the same arginine involved in the surface charge inter-
action. Csp8 also has an additional charge–charge inter-
action from a second arginine residue (Arg258), which
follows the helix–turn–helix insertion loop. This is in
agreement with recent findings in which a similar peptide
inhibitor is complexed with Csp8 [21]. Analysis of
Figure 5 shows that the P3 glutamic acid of the Ac-
DEVD-CHO inhibitor is oriented towards this second (i.e.
Arg258) arginine residue on the protein surface of Csp8. A
crystallographic water molecule is observed binding to the
conserved arginine for Csp3, Csp7 and Csp8.
The differences in size of the S4 loop among the four cas-
pases in this study are striking. These loops involve the
following residues: Csp1 (378–386); Csp3 (244–262), Csp7
(270–288); and Csp8 (451–463). Figure 2b illustrates that
this loop is largest for Csp3 and Csp7. Despite the fact
that this loop is identical in length for these two closely
related caspases, they are only 63% identical in composi-
tion. The same loop is shorter for Csp8 and shorter still for
Csp1. In each case, there is an interaction between the P4
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Figure 3
Sequence alignment of Csp1, Csp3, Csp7 and Csp8. The alignment
was heavily biased upon the superposition of conserved secondary
structural elements and active site residues of Csp1, Csp3, Csp7 and
Csp8. The alignment was performed with the MVP program [47] and
then adjusted manually. Boxed residues denote direct or water-
mediated interactions with Ac-DEVD-CHO as shown in Figure 4.
Amino acid color coding is as follows: green, hydrophobic; purple,
basic; orange, acidic; yellow, histidine; black, proline, glycine; gray,
serine and threonine; pink, asparagine and/or glutamine.
CSP01 155 IMDKSSRTRLALIICNEEF----------DSIPRR TGAEVDITGMTMLLQ
CSP03 37  YKMDYPEMGLCIIINNKNF-------HKSTGMTSR SGTDVDAANLRETFR
CSP07 60  YNMNFEKLGKCIIINNKNF-------DKVTGMGVR NGTDKDAEALFKCFR
CSP08 226 YQMKSKPRGYCLIINNHNFAKAREKVPKLHSIRDR NGTHLDAGALTTTFE
CSP01 195 NLGYSVDVKKNLTASDMTTELEAFAHRPEHKTSDSTFLVFMSH GIREGIC
CSP03 80 NLKYEVRNKNDLTREEIV-ELMRDVSKEDHSKRSSFVCVLLSH GEEGIIF
CSP07 103 SLGFDVIVYNDCSCAKMQ-DLLKKASEEDHTNAACFACILLSH GEENVIY
CSP08 276 ELHFEIKPHDDCTVEQIY-EILKIYQLMDHSNMDCFICCILSH GDKGIIY
CSP01 245 GKKHSEQVPDILQLNAIFNMLNTKNCPSLKDKPKVIIIQ AC RGDSPGVVW
CSP03 129 GTNG------PVDLKKITNFFRGDRCRSLTGKPKLFIIQ AC RGTELDCGI
CSP07 152 GKDG------VTPIKDLTAHFRGDRCKTLLEKPKLFFIQ AC RGTELDDGI
CSP08 325 GTDGQE-----APIYELTSQFTGLKCPSLAGKPKVFFIQ AC QGDNYQKGI
CSP01 295 FKDSVGVSGNLSLPTTEEFEDDAI----------KKAHIEKDFIAFCSST
CSP03 173 ETDSGVDDDMACH----------------------KIPVDADFLYAYSTA
CSP07 196 QADSGPINDTDANPRY-------------------KIPVEADFLFAYSTV
CSP08 370 PVETDSEEQPY-------------LEMDLSSPQTRYIPDEADFLLGMATV
CSP01 335 PDNV SWRHPTMGSVFIGRLIEHMQEYACSCDVEEIFRKVRFSFEQPDG--
CSP03 201 PGYY SWRNSKDGSW FIQSLCAMLKQYADKLEFMHILTRVNRKVATEFESF 
CSP07 227 PGYY SWRSP GRGSWFVQALCSILEEHGKDLEIMQILTRVNDRVARHFESQ 
CSP08 407 NNCV SYRNPAEGTW YIQSLCQSLRERCPRGDDILTILTEVNYEVSNK---
CSP01 383 --------R AQMPTTERVTLTRCFYLFPGH
CSP03 251 SFDATF HAKKQIPCIV-SMLTKELYFYH
CSP07 277 SD DPHF HEKKQIPCVV-SMLTKELYFSQ
CSP08 454 --DD KKNMGKQMPQPT-FTLRKKLVFPSD
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aspartic acid of the Ac-DEVD-CHO inhibitor and a
residue in this loop. 
The major differences for the binding of Ac-DEVD-CHO
to Csp1, Csp3, Csp7 and Csp8 occur at the P4 aspartic acid
and the acetylated amino terminus of the tetrapeptide. All
of the caspases included in this study involve either direct
or indirect binding by the S4 loop. Figure 4 shows that
Csp1 interacts with the P4 aspartic sidechain directly
through an interaction with Arg383. Csp3 interacts via the
backbone nitrogen of Phe250 and the sidechain of Asn208.
In this case, there is also an interaction of the P4 aspartic
acid with Trp214 through a water-mediated hydrogen
bond. Additionally, the P4 backbone nitrogen and car-
bonyl oxygen forms hydrogen bonds with two different
water molecules, both of which form hydrogen bonds with
the carbonyl group of Phe250. Csp7 binds the P4 aspartic
acid through both backbone and sidechain involvement of
Gln276. The P4 backbone nitrogen forms an additional
hydrogen bond with the backbone carbonyl of Gln276
while the P4 backbone carbonyl oxygen forms a hydrogen
bond to the same crystallographic water molecule involved
in another hydrogen bond with the P2 backbone nitrogen.
It is interesting to note that, although the Csp3 and Csp7
sequences share 57% and 67% similarity (Figure 3), there
are significant differences in and around the S4-binding
region. The replacement of Csp3 residues (Asn208,
Ser209, Asp211, Phe250, Phe252, Thr255, and Ala258 by
their respective Csp7 residues (Ser234, Pro235, Arg237,
Gln276, Asp278, His281 and Glu284) has changed the
chemical content (Figure 5) in the S4-binding region to be
more hydrophilic. 
Csp8 interacts directly with the P4 aspartate residue via
the sidechain nitrogens of Asn414 and Trp420 that are
not part of the S4 loop. However, the P4 aspartate 
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Schematic showing hydrogen bonding and van der Waals interactions of covalently bound Ac-DEVD–thiohemiacetal with binding-site residues of
(a) Csp1, (b) Csp3, (c) Csp7 and (d) Csp8. Wat, water molecule.
carbonyl oxygen interacts with Asp455 via a water-medi-
ated hydrogen bond.
The N-acetyl P4 capping group also exhibits differences in
hydrogen bonding and hydrophobic interactions. Csp1,
Csp7 and Csp8 all make a hydrophobic interaction
between the N-acetyl terminal methyl group and a proline
(Figure 4). Csp3 lacks this hydrophobic interaction, but
makes two hydrogen bonds with Ser209, one involving the
Ser209 backbone nitrogen, the other with the Ser209
sidechain. Csp7 forms a water-mediated hydrogen bond
with both the backbone nitrogen and sidechain of Asp278.
For Csp8, the N-acetyl carbonyl oxygen forms a hydrogen
bond to the sidechain of Asn414. No hydrogen bond is
observed between Csp1 and the N-acetyl group. One final
observation regarding differences in binding the N-acetyl
group occurs between Csp3 and the other three caspases
included in this study. As mentioned above, there are two
strong hydrogen bonds between the N-acetyl group and
Ser209 of Csp3. In Csp1, Csp7 and Csp8, however, the
residue corresponding to Ser209 is a proline; any hydrogen-
bonding interactions of the N-acetyl group involves differ-
ent residues. Owing to the inability of the proline ring to
form hydrogen bonds, the P4 N-acetyl group is translated
~2.5 Å. Figure 6 illustrates this shift between Csp3 and
Csp7. These are members of the same caspase subfamily.
The differences in hydrogen bonding of the P4 and 
N-acetyl groups with the associated caspase residues
results in a variable width of the S4 site with Csp8 having
the widest S4 site, followed by Csp1 (Figure 5); Csp3 and
Csp7 have a narrower S4 site. For Csp3 and Csp7, the
reduced width in the S4 site can be directly linked to the
greater extent of the hydrogen-bond network between
this portion of the tetrapeptide and the S4 site which
serves to ‘pull’ the walls of the S4 pocket towards the P4
group. On this point, the electrostatic potential surfaces
illustrated in Figure 5 are informative. The surface poten-
tial of Csp7 is unique because it is the only caspase of the
four studied that has an unpaired basic residue (Arg237)
near the P4 aspartic acid. Csp1 and Csp8 also have basic
residues that contribute to the electropositive portion of
the surface potential in this region, but they also have
counterbalancing negative charges near by. Csp3 has a
neutral S4 region. These observations suggest that, in
terms of structure and associated surface potential, there
should be no absolute requirement for a negatively
charged group at P4.
On the prime side, Csp8 differs from the others by the pres-
ence of a helix–turn–helix insertion ranging from residues
245–253 (Figure 2c). This agrees with the recently reported
Csp8 structures expressed in Escherichia coli [21,22] that also
possess some helical content to this insertion loop. An
analysis of a sequence alignment derived from superposi-
tion of the four caspase structures (Figure 3) suggests this
insertion to be unique to Csp8. Three of the lysines in this
region (Lys246, Lys250, Lys253) were mutated to arginine
in order to obtain diffraction quality crystals. A comparison
of wild-type and the mutant form of Csp8 used to deter-
mine the crystal structure showed that both enzymes
appear to be indistinguishable, yielding a kcat/Km of
1 × 105 M–1s–1 for Ac-DEVD–aminomethylcoumarin (Ac-
DEVD–AMC) hydrolysis. Two of these mutated arginines
are stabilized by a salt bridge with nearby glutamic residues
(Arg250 with Glu249, Arg253 with Glu330, Arg246 with a
glutamic acid from a symmetry-related neighbor. None of
these mutated residues is oriented in the prime side region,
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Figure 5
Electrostatic potential mapped onto
molecular surface for binding-site residues of
Csp1, Csp3, Csp7 and Csp8. Blue depicts
areas of positive electrostatic potential, red
depicts areas of negative electrostatic
potential and white represents areas of
neutral electrostatic potential. The molecular
surface and electrostatic potential were
calculated using GRASP [48]. 
nor are they in close proximity to the tetrapeptide inhibitor.
Leu254, from this helix–turn–helix insertion, appears to
point inward towards the prime side region. The spatial
position of the helix–turn–helix insertion for Csp8 most
closely resembles a short insertion loop of Csp1 (Figure 2c:
residues 249–254) which is conserved among the members
of the Csp1 family.
Structural insights and binding specificity 
On the basis of positional scanning of a combinatorial sub-
strate library, Thornberry et al. [26] were able to deter-
mine the optimal tetrapeptide substrate sequences for ten
human caspases. In this study, a cleavable Asp-AMC was
held constant at P1 and the amino acids at P2 through P4
were varied. They found that group I (Csp1, Csp4 and
Csp5) caspases loosely preferred the sequence WEHD,
while group II (Csp2, Csp3 and Csp7) caspases strongly
preferred the motif DEXD. Group III (Csp6, Csp8, Csp9
and Csp10) caspases preferred the motif (L/V)EXD. This
information was subsequently used to design and investi-
gate tetrapeptide aldehyde inhibitors [7]. Some traditional
reversible inhibitors and irreversible inhibitors such as
Z–VAD–FMK were also included in the study. 
Reported Ki values (nM) from reference sequences [7] for
Ac-DEVD–CHO against Csp1, Csp3, Csp7 and Csp8,
respectively, are as follows: 18 nM, 0.23 nM, 1.6 nM and
0.92 nM. Although this tetrapeptide inhibitor is most
potent against group II and III caspases, it is the only
reported tetrapeptide aldehyde that significantly inhibits
representatives from all three groups of caspases. The fact
that all caspases considered here can accommodate a
valine at P2 attests to the general tolerability of branched
amino acids at this position. However, branched amino
acids at P2 tend to produce less optimal substrates against
Csp1, Csp4 and Csp5 [26] and are typically not present in
the best inhibitors for Group I caspases. In general, large
groups are tolerated as both substrates and inhibitors for
all three caspase subfamilies and even though tetra
peptide substrates containing tryptophan, phenylalanine,
and tyrosine at P2 are suboptimal, histidine-containing
tetrapeptide substrates were generally good against 
group I and III caspases [26]. Additionally, in a previous
crystallographic study, a nonpeptidic pyridone aldehyde
inhibitor containing a large 6-benzyl substituent on the
pyridone ring was found to place the phenyl ring of the
benzyl group over the S2 site in Csp1 [27]. 
The optimal residue identified by the combinatorial
tetrapeptide substrate library [26] at the P3 position for
all three groups of caspases is glutamic acid. All four cas-
pases in the present study make at least one
charge–charge interaction with the P3 glutamic acid. The
nature of this interaction involves an absolutely con-
served arginine; however, this salt bridge is on the
surface of the protein and is solvent exposed. In terms of
substrate specificity, such an interaction might be
optimal in terms of recognition and proper positioning of
the peptide backbone, but would be expected to con-
tribute minimally to the overall binding energetics [28].
This is illustrated by the inhibitor Ac-YVAD-CHO which
shows good inhibitory potency against Csp1 and modest
inhibitory potency against group III caspases. Although
the surface charge–charge interaction(s) would be lost,
the P3 valine would be expected to still make the
required backbone hydrogen bonds and a potential
hydrophobic interaction with a either a proline (Csp1,
Csp7, Csp8) or the β carbon of serine (Csp3). The
branched P3 valine would also serve to maintain the
rigidity of the extended tetrapeptide inhibitor and could
potentially improve cell potency due to one less formal
charge on the molecule. A recent report of pep-
tidomimetic caspase inhibitors shows reasonably potent
inhibition of multiple caspases in a compound class that
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Figure 6
A stereoview diagram showing the
superposition of Csp3 (orange) with Csp7
(cyan) generated by RIBBONS. The N-acetyl
group of the tetrapeptide inhibitor, Ac-DEVD-
CHO, bound to Csp7 (green) is translated
~2.5 Å relative to that in Csp3 (dark brown)
due to the substitution of proline (235) for
serine at the same position of the
P4-binding site.
would be incapable of making a charge–charge inter-
action with the conserved S3 arginine [29]. 
In terms of both substrate specificity and inhibitor selec-
tivity, the P4 position offers the most variability. In
general, both hydrophobic groups and the anionic aspar-
tate are tolerated at the P4 position for both substrates and
inhibitors. For group II and III caspases, a tryptophan
rests at the bottom of the S4 pocket. For group I caspases,
this same residue is a smaller hydrophobic amino acid (e.g.
Val348 in Csp1). The binding of Ac-DEVD-CHO to Csp1
produces fewer total hydrogen bonds with S4 residues rel-
ative to the other caspases studied, and this allows for a
wider S4 pocket. The combination of fewer hydrogen
bonds and a neutral electrostatic potential in this portion
of the binding site suggests that group I caspases could
accommodate larger hydrophobic groups at S4, thereby
providing an avenue to gain selectivity in the design of
inhibitors. The combinatorial tetrapeptide substrate study
[26] showed that WEHD was the optimal substrate for
Csp1 and was also a good substrate for the other group I
caspases, Csp4 and Csp5. However, leucine was roughly
equal to tryptophan at P4 as a substrate for these two cas-
pases. Group II caspases were shown to have a strong pref-
erence for substrates with aspartic acid at P4. As alluded to
above, the replacement of hydrophobic residues in Csp3
by charged or hydrophilic residues in Csp7 might allow
these two seemingly redundant caspases to act on differ-
ent substrates in different cell types or cellular compart-
ments [30,31] even though their in vitro substrate
preferences are identical. Group III caspases prefer either
valine or leucine at the P4 position. Interestingly, in terms
of inhibitors, Ac-WEHD-CHO showed the most potent
inhibition against Csp1, suggesting that the valine at the
bottom of the S4 pocket leaves enough room for the P4
tryptophan to be accommodated [7]. Although Csp8 has a
large tryptophan residue at the bottom of the S4 pocket,
this portion of the binding site is fairly wide and can
accommodate the P4 group of Ac-WEHD-CHO. Similar
trends are observed for inhibitors containing tyrosine or
benzyloxycarbonyl groups at P4. Additionally, the first
selective Csp1 inhibitor to reach clinical trials, VX-740,
possesses an isoquinoline group at P4. The X-ray crystallo-
graphic structure of this inhibitor clearly shows the P4 iso-
quinoline fitting snugly in the S4 pocket (Mullican et al.,
unpublished observations). Thus, although it is possible to
design selective Csp1 inhibitors by incorporation of large
hydrophobic groups at P4, it is not clear that one can take
advantage of the P4 position to design selective inhibitors
of other caspases.
Significance
The caspase family has continued to evoke intense inter-
est in the world of biology and biomedical research.
Caspase inhibition has produced desired pharmacologi-
cal effects in animal models for stroke, myocardial
infarction, traumatic brain injury, liver disease and
interleukin-1β-mediated inflammatory conditions. Bio-
chemical studies further suggest the utility of caspase
inhibitors in the treatment of various neurodegenerative
diseases [32–37]. Despite this, much caspase biology
remains to be uncovered, and it is still difficult to assess
the relative contribution of individual caspases to effect
specific cellular events without the benefit of specific
inhibitors. 
A better understanding of caspase structures spanning
all of the caspase subfamilies provides the framework
for the design of potent and selective inhibitors of indi-
vidual caspases. These molecules will, in turn, help
uncover the biology in this field and open the way for the
use of caspase inhibitors in the treatment of relevant dis-
eases.
It is hoped that the crystallographic complexes of Csp1,
Csp3, Csp8 and the new structure of Csp7 bound to the
same tetrapeptide aldehyde inhibitor, Ac-DEVD-CHO,
presented here can contribute towards this goal. 
Materials and methods
Expression and purification of Csp1, Csp3, Csp7 and Csp8 
Recombinant human Csp1 was expressed in E. coli as an insoluble p32
protein spanning residues 120–404 of the p45 precursor [38]. The
insoluble p32 protein was solubilized and purified under chaotropic con-
ditions, then refolded and autoprocessed in vitro, producing the
p20 and p10 active subunits. Details, including previous 
X-ray crystallographic analyses, have been described elsewhere [16,17].
Csp3 (residues 29–277) and Csp7 (residues 1–303) containing an
amino-terminal His6 affinity tag and thrombin-cleavable site were
expressed in E. coli [39,40]. Both caspases were soluble and active as
their p20–p10 subunits, yielding 0.05 mg/g and 1 mg/g cells of Csp3
and Csp7, respectively. For purification of either protein, cell paste was
resuspended in 10 volumes of 50 mM HEPES buffer containing 10%
(v/v) glycerol, 300 mM NaCl, 5 mM β-ME, 0.05% (w/v) β-OG, 25 mM
imidazole, 0.1 mM PMSF, pH 8.0 at 4°C. Following mechanical disrup-
tion of the cells, the soluble fraction was harvested by centrifugation at
30,000 ×g for 30 min at 4°C. The supernatant was incubated batch-
wise overnight with 1 ml Ni-affinity resin (Qiagen, Valencia, CA) per
5–10 mg of expected Csp3 or Csp7. The resin was washed with 50
column-volumes of the extraction buffer, followed by 50 column-
volumes of the extraction buffer adjusted to pH 7.0. Csp3 and Csp7
were eluted with 50 mM and 300 mM imidazole, respectively, in 50 mM
HEPES, pH 7.0 containing 10% (v/v) glycerol, 100 mM NaCl, 5 mM 
β-mercaptoethanol (β-ME). 
Recombinant Csp8 (residues 233–479) was expressed as an amino-
terminal histidine-tagged fusion in High-five insect cells using a 
baculovirus expression vector system by conventional methods [41].
Crystallization of Csp8–Ac-DEVD-CHO was enhanced by three
Lys→Arg point mutations (at residues 246, 250 and 253), and removal
of Pro370 and Val371, which appeared absent from other caspases in
sequence alignments. Csp8 was processed intracellularly and
secreted into the media during expression. The cell culture media was
centrifuged at 1600 ×g to remove cells, and the supernatant (~pH 6.4)
adjusted to 50% (w/v) ammonium sulfate and stirred gently for 60 min
on ice. After centrifugation at 54,000 ×g for 45 min at 4°C, the super-
natant was decanted, 0.2 µm filtered and the ammonium sulfate con-
centration increased to 85% (w/v) and stirred for another 60 min on
ice. Centrifugation at 54,000 ×g for 45 min at 4°C resulted in the pre-
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cipitation of Csp8. Pellets were resuspended in 2% of the starting
volume of the media using 100 mM HEPES, pH 8.0, containing
100 mM NaCl, 10% glycerol (v/v) and 5 mM β-ME. The solution was
incubated with 1 ml Talon affinity resin (Clontech, Palo Alto, CA) per
5–10 mg expected Csp8 and gently mixed overnight at 4°C. The resin
washed with 150 column volumes of 20 mM HEPES, pH 7.0, contain-
ing 100 mM NaCl, 10% glycerol (v/v) and 5 mM β-ME. A second wash
of 50 column volumes was performed using the same buffer, with
25 mM imidazole. Csp8 was eluted with wash buffer adjusted to
350 mM imidazole.
Characterization of triple mutant Csp8
Wild-type and mutant Csp8 enzymes were characterized using the 
fluorogenic substrate Ac-DEVD–AMC (Alexis Biochemicals, San
Diego, CA). The concentrations of active enzyme were determined by
active-site titration with Ac-DEVD-CHO (Peptides International,
Lousiville, KY). All assays were performed in 100 mM HEPES, pH 8,
containing 100 mM NaCl, 5 mM DTT and 0.1% (w/v) CHAPS at 37°C
using a 96-well Fmax plate reader (Molecular Devices, Sunnyvale, CA).
The Ac-DEVD-AMC substrate concentration was varied between 2 and
100 µM and the reaction was initiated by addition of 2 nM enzyme.
Enzyme kinetic data were analyzed by nonlinear regression in the
program EZ-Fit (Perrella Scientific, Amherst, NH). 
Preparation of Csp–Ac-DEVD-CHO crystallographic samples
Details of protein purification and crystallization of the Csp1–Ac-DEVD-
CHO complex has been reported [17]. Metal affinity purified Csp3,
Csp7 or Csp8 were inhibited by addition of a two-fold molar excess of
Ac-DEVD-CHO (Peptides International). The amino-terminal His6 tag
was then removed from Csp3, Csp7 or Csp8 by thrombin cleavage
(20 units of thrombin per mg caspase) at 37°C for 60 min. Thrombin
was removed by a 5 min incubation with 100 µl of benzamidine
sepharose. The free His6 tag and aggregated caspase were removed
by size-exclusion chromatography using a column (60 × 1.5 cm)
packed with Superdex-75 resin (Pharmacia, Uppsala, Sweden). The
column was equilibrated at 4°C in 20 mM HEPES, pH 7.0, containing
10% glycerol (v/v), 100 mM NaCl, 5 mM β-ME at a flow rate of 1 ml
min–1. Light-scattering (PD-2000, Precision Detectors, Franklin, MA)
analyses during size-exclusion chromatography identified aggregated
protein, which was excluded from the pooled fractions. Csp1–Ac-
DEVD-CHO was purified on the same size-exclusion column except
50 mM citrate, pH 6.5, containing 2 mM DTT buffer was used. After
size-exclusion, equimolar Ac-DEVD-CHO was added prior to concen-
tration of the Csp–Ac-DEVD-CHO co-complexes for crystallization. All
protein samples were stored at –70°C.
Crystals of inhibited Csp3 were grown by vapor diffusion and macro-
seeding. Thousands of microcrystals were initially obtained in 12 h
when protein (4.6 mg ml–1 in 20 mM Na-HEPES, 2.0 mM DTT, 0.1 M
NaCl, 10% glycerol, pH 7.0) was mixed with reservoir (0.2 M ammo-
nium acetate, 0.1 M sodium citrate, 30% w/v PEG 4000) at a
3 µl : 2 µl protein solution : reservoir ratio and allowed to stand at
room temperature. A crystallization droplet setup in the same way but
with 2% (v/v) methyl-pyrrolidinone (MeP) added to the reservoir pro-
duced no crystals. A microcrystal was then transferred to this second
drop and this seed crystal grew over 10 days to a size of
0.4 mm × 0.3 mm × 0.25 mm. 
The autoproteolyzed active form Csp7 was inhibited by titrating Ac-
DEVD-CHO into the protein sample. The complex was further purified
by size-exclusion chromatography. Pooled fractions were concentrated
to about 5 mg/ml for crystallization. Slow vapor diffusion was used to
obtain X-ray quality crystals of the Csp7–Ac-DEVD-CHO complex over
a few weeks at 4°C.
Csp8 was titrated with Ac-DEVD-CHO (12.0 mg/ml, 20 mM HEPES
pH 7.0, 0.1 M NaCl, 5.0 mM β-ME) and was subsequently added to a
reservoir solution (0.1 M potassium phosphate, pH 6.0, 5% t-butanol,
40% (w/v) ammonium sulfate) at 2 µl : 2 µl ratio and suspended over
1.0 ml of reservoir at room temperature. A single crystal was harvested
within two weeks and has dimensions of 0.40 × 0.20 × 0.10 mm. The
same crystal was flash cooled to 170 K in a nitrogen gas stream prior
to data collection. 
Data collection, structural solution and refinement
Crystals of Csp1–Ac-DEVD-CHO and Csp3–Ac-DEVD-CHO were
mounted in glass capillaries for X-ray data collection at –7°C and –4°C,
respectively. X-ray data of both Csp1–Ac-DEVD-CHO and Csp3 com-
plexes were collected on an Raxis IIC image plate equipped with
Rigaku rotating anode generator and processed using software pro-
vided by the manufacturers (Molecular Structures Corp., Woodlands,
TX). R-merge for the data was 6.1%. at 2.2 Å resolution. Analysis of the
unit cell dimensions suggested that each asymmetric unit contained
two Csp3 heterodimers. A polyalanine model of a single Csp1 het-
erodimer was used to obtain a successful rotation and translation func-
tion solution for a Csp3 heterodimer using the program AMoRe [42].
The first solution was then fixed while a second polyalanine model was
tried in the rotation and translation function. Combining the two solu-
tions produced a polyalanine model for the Csp3 dimer of het-
erodimers with an R-factor of 45.1% for all observed reflections
between 8 and 2.8 Å resolution, and an R-free of 47.5% for 10% of the
reflections set aside at the start of the refinement. The resolution of the
maps and model was gradually increased to 2.2 Å resolution by cycles
of model building, positional refinement and thermal factor refinement,
interspersed with torsional dynamics runs. All model refinement was
carried out using the X-PLOR [43] suite of programs.
Crystals of the Csp7–Ac-DEVD-CHO complex were transferred to cry-
oprotectant and flash-cooled to 100K in nitrogen gas stream prior to
data collection. The diffraction images were recorded on charge-
coupled device (CCD) 2X2K detector at Brookhaven National Labora-
tories (BNL, Brookhaven, NY). The data were processed using DENZO
and SCALPACK software [44]. The crystals have unit cell dimensions
of 88.2 Å, 88.2 Å, 186.2 Å, α = 90.0°, β = 90.0°, γ = 120.0°, and
belong to space group P3221. Assuming that there is one tetramer in
the asymmetric unit, the calculated Matthew’s specific volume was
2.6 Å3/d. The structure was solved by molecular replacement methods
using a truncated Csp3 tetramer molecule as the searching template.
The initial R-factor and correlation coefficient factors are 44% and
65%, respectively. A polyalanine model from the solution was first
refined against data between 8.0 Å and 3.0 Å. The sidechains of indi-
vidual amino acids were modeled into the electron density map accord-
ing to the protein sequence. The model was refined using X-PLOR and
manually corrected using QUANTA (QUANTA97, Molecular Simula-
tions, Inc). The final model has a full tetramer assembly of 654
residues, two sulfate anions and 374 water molecules. 
A single crystal of Csp8–Ac-DEVD-CHO complex was flash-cooled in
a nitrogen gas stream prior to the synchrotron data collection at BNL.
Data was recorded on a 2X2K CCD image plate mounted on X25
beam line. The space group of the crystal was determined as C2221
with unit cell dimensions of 62.12 Å, 344.33 Å, 190.99 Å, α = 90.0,
β = 90.0, γ = 90.0. The Matthew’s specific volume calculation [45] sug-
gested that there are three independent tetrameric molecules in the
asymmetric unit giving a calculated solvent content of 54%. The crystal
diffracts anisotropically along the a*, b*, and c* axes to 2.35 Å, 2.80 Å
and 2.65 Å, respectively. The data set was processed using DENZO
and SCALPACK software to a resolution of 2.65 Å. The structure solu-
tion was obtained by using AMoRe and using a truncated Csp3
tetramer molecule as searching template. Rigid-body and positional
refinement of the polyalanine model was initially carried out using X-
PLOR. The sidechains, insertions and deletions of the molecule were
modeled into the electron density map manually using QUANTA pro-
grams. The final model contains 1454 amino acids, 316 solvent mol-
ecules and six Ac-DEVD-CHO compounds covalently attached to the
active site cysteine residue.
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Accession numbers
The coordinates of the Csp-7–Ac-DEVD-CHO structure have been
deposited with the Protein Data Bank under the accession code 1F1J.
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